Biostem Technologies, Inc. (NASDAQ:BSEM) Sees Significant Decline in Short Interest

Biostem Technologies, Inc. (NASDAQ:BSEM) was the recipient of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 119,203 shares, a decrease of 78.5% from the August 15th total of 554,233 shares. Currently, 0.7% of the shares of the stock are sold short. Based on an average daily volume of 89,169 shares, the days-to-cover ratio is currently 1.3 days.

Biostem Technologies Stock Performance

Shares of NASDAQ:BSEM opened at $4.18 on Friday. The firm has a market capitalization of $74.61 million, a PE ratio of -2.61 and a beta of 0.12. Biostem Technologies has a 52-week low of $2.25 and a 52-week high of $8.40. The firm has a fifty day moving average of $3.62 and a 200 day moving average of $4.46.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Wall Street Zen upgraded Biostem Technologies to a “sell” rating in a research report on Saturday, September 5th. Weiss Ratings started coverage on Biostem Technologies in a research note on Wednesday, August 19th. They issued a “sell (d-)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Biostem Technologies Company Profile

BioStem Technologies, Inc (NASDAQ: BSEM) is a biotechnology company focused on regenerative medicine and biologic tissue products. Through its operating businesses, the company develops, manufactures and distributes human tissue allografts intended to support wound care, surgical procedures and other regenerative applications.

Its product portfolio includes placental-tissue-based products, including amniotic membrane and related graft technologies. These products are designed for use by health-care professionals in applications such as wound management and tissue repair.